Name | Type | Posted | Actions |
|---|---|---|---|
75N98019R00005_Amendment_0002.pdf | Apr 19, 2019 | ||
Q&A.pdf | Apr 19, 2019 | ||
sectionk_june2017.pdf | Apr 19, 2019 | ||
75N98019R00005.pdf | Mar 29, 2019 | ||
Quality_Agreement_template.pdf | Mar 8, 2019 | ||
Sample_Task_Order.pdf | Mar 8, 2019 | ||
75N98019R00005.pdf | Mar 8, 2019 | ||
DFMC_Final.pdf | Mar 8, 2019 | ||
Proposal_Intent_Response_Form.pdf | Mar 8, 2019 |
Drug Formulation and Manufacturing Program
Contact and place of performance
Robert Burdette
Not specified
This notice is being amended to provide questions and answers and provide the amened solicitation. As a result of this amendment the proposal submission deadline has been extended.
The Drug Formulation and Manufacturing Program solicitation, identified as 75N98019R00005, is a federal procurement categorized under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC code 99. This opportunity is designated as an SBP (Small Business Program) set-aside. The program requires drug formulation and manufacturing services, with specific administrative materials including a Quality Agreement template and a Sample Task Order provided among the nine total attachments.
Recent updates to this notice include the publication of an amended solicitation and a list of official questions and answers. As a result of these amendments, the proposal submission deadline has been extended to May 7, 2019. Robert Burdette is the designated point of contact for this requirement. Supporting documentation includes Amendment 0002, Section K files, and various technical attachments released between March and April 2019.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.